Tarsus Pharmaceuticals (TARS) to Release Earnings on Tuesday

Tarsus Pharmaceuticals (NASDAQ:TARS) is projected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Tarsus Pharmaceuticals to post earnings of ($0.68) per share and revenue of $58.80 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Tarsus Pharmaceuticals Stock Down 1.8 %

Shares of NASDAQ TARS opened at $47.84 on Monday. The company’s 50-day simple moving average is $51.87 and its 200-day simple moving average is $42.75. Tarsus Pharmaceuticals has a 52-week low of $20.08 and a 52-week high of $57.28. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -12.56 and a beta of 1.01. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TARS. Barclays lifted their target price on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. Guggenheim reiterated a “buy” rating on shares of Tarsus Pharmaceuticals in a research report on Monday, February 10th. Oppenheimer lifted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, The Goldman Sachs Group boosted their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $56.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.